In this issue:
Efficacy and safety of nivolumab plus relatlimab
Impacts of Vitamin D on anti-PD-1 therapy
Molecular features of DedM
PFS of patients after anti-PD-1 discontinuation
Updated HRQoL results from RELATIVITY-047 trial
Assessing first-line treatment options for melanoma patients
Narrow and wide excisions linked to local recurrence
MC1R genotypes and risk of melanoma
T1 melanomas treated with 5 or 10mm margins
Accuracy of RCM
Please login below to download this issue (PDF)